These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

361 related articles for article (PubMed ID: 27467136)

  • 1. Advances in treatment of metastatic renal cell carcinoma.
    Gong J; Gerendash B; Dizman N; Khan A; Pal SK
    Curr Opin Urol; 2016 Sep; 26(5):439-46. PubMed ID: 27467136
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Lenvatinib therapy for the treatment of patients with advanced renal cell carcinoma.
    Glen H
    Future Oncol; 2016 Oct; 12(19):2195-204. PubMed ID: 27339111
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Second-line systemic therapy in metastatic renal-cell carcinoma: A review.
    Jain RK; Gandhi S; George S
    Urol Oncol; 2017 Nov; 35(11):640-646. PubMed ID: 28887097
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Lenvatinib for use in combination with everolimus for the treatment of patients with advanced renal cell carcinoma following one prior anti-angiogenic therapy.
    O'Reilly A; Larkin J
    Expert Rev Clin Pharmacol; 2017 Mar; 10(3):251-262. PubMed ID: 28224821
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Hypertension Caused by Lenvatinib and Everolimus in the Treatment of Metastatic Renal Cell Carcinoma.
    Bendtsen MAF; Grimm D; Bauer J; Wehland M; Wise P; Magnusson NE; Infanger M; Krüger M
    Int J Mol Sci; 2017 Aug; 18(8):. PubMed ID: 28796163
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Emerging growth factor receptor antagonists for the treatment of renal cell carcinoma.
    Zahoor H; Rini BI
    Expert Opin Emerg Drugs; 2016 Dec; 21(4):431-440. PubMed ID: 27690664
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Lenvatinib in the management of metastatic renal cell carcinoma: a promising combination therapy?
    De Lisi D; De Giorgi U; Lolli C; Schepisi G; Conteduca V; Menna C; Tonini G; Santini D; Farolfi A
    Expert Opin Drug Metab Toxicol; 2018 Apr; 14(4):461-467. PubMed ID: 29557694
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cabozantinib for Renal Cell Carcinoma: Current and Future Paradigms.
    Abdelaziz A; Vaishampayan U
    Curr Treat Options Oncol; 2017 Mar; 18(3):18. PubMed ID: 28286925
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Combination antiangiogenic tyrosine kinase inhibition and anti-PD1 immunotherapy in metastatic renal cell carcinoma: A retrospective analysis of safety, tolerance, and clinical outcomes.
    Laccetti AL; Garmezy B; Xiao L; Economides M; Venkatesan A; Gao J; Jonasch E; Corn P; Zurita-Saavedra A; Brown LC; Kao C; Kinsey EN; Gupta RT; Harrison MR; Armstrong AJ; George DJ; Tannir N; Msaouel P; Shah A; Zhang T; Campbell MT
    Cancer Med; 2021 Apr; 10(7):2341-2349. PubMed ID: 33650321
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Lenvatinib, everolimus, and the combination in patients with metastatic renal cell carcinoma: a randomised, phase 2, open-label, multicentre trial.
    Motzer RJ; Hutson TE; Glen H; Michaelson MD; Molina A; Eisen T; Jassem J; Zolnierek J; Maroto JP; Mellado B; Melichar B; Tomasek J; Kremer A; Kim HJ; Wood K; Dutcus C; Larkin J
    Lancet Oncol; 2015 Nov; 16(15):1473-1482. PubMed ID: 26482279
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The Efficacy of Lenvatinib Plus Everolimus in Patients with Metastatic Renal Cell Carcinoma Exhibiting Primary Resistance to Front-Line Targeted Therapy or Immunotherapy.
    Hamieh L; Beck RL; Le VH; Hsieh JJ
    Clin Genitourin Cancer; 2020 Aug; 18(4):252-257.e2. PubMed ID: 32291161
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Optimal management of metastatic renal cell carcinoma: current status.
    Escudier B; Albiges L; Sonpavde G
    Drugs; 2013 Apr; 73(5):427-38. PubMed ID: 23572408
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Overview of Current and Future First-Line Systemic Therapy for Metastatic Clear Cell Renal Cell Carcinoma.
    Gill DM; Hahn AW; Hale P; Maughan BL
    Curr Treat Options Oncol; 2018 Jan; 19(1):6. PubMed ID: 29368125
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Lenvatinib for the treatment of kidney cancer.
    Študentová H; Vitásková D; Melichar B
    Expert Rev Anticancer Ther; 2018 Jun; 18(6):511-518. PubMed ID: 29737893
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Efficacy and Safety of Sequential Use of Everolimus in Patients With Metastatic Renal Cell Carcinoma Previously Treated With Bevacizumab With or Without Interferon Therapy: Results From the European AVATOR Study.
    Thiery-Vuillemin A; Theodore C; Jacobasch L; Schmitz J; Papandreou C; Guillot A; Emmanouilides C; Slimane K; Kelkouli N; Kim S; Nguyen Tan Hon T
    Clin Genitourin Cancer; 2015 Jun; 13(3):231-8. PubMed ID: 25456838
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Overview of current and future systemic therapy for metastatic renal cell carcinoma.
    Osawa T; Takeuchi A; Kojima T; Shinohara N; Eto M; Nishiyama H
    Jpn J Clin Oncol; 2019 May; 49(5):395-403. PubMed ID: 30722031
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Lenvatinib for the treatment of renal cell carcinoma.
    Roviello G; Corona SP; Bozza G; Aieta M; Generali D; Rodriquenz MG; Mileo AM; Imperatori M; Ianza A; Conca R; Sobhani N
    Expert Opin Investig Drugs; 2018 May; 27(5):507-512. PubMed ID: 29718721
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Lenvatinib in combination with everolimus in patients with advanced or metastatic renal cell carcinoma: A phase 1 study.
    Matsubara N; Naito Y; Nakano K; Fujiwara Y; Ikezawa H; Yusa W; Namiki M; Okude T; Takahashi S
    Int J Urol; 2018 Nov; 25(11):922-928. PubMed ID: 30129060
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Cabozantinib in the treatment of advanced renal cell carcinoma: design, development, and potential place in the therapy.
    Grassi P; Verzoni E; Ratta R; Mennitto A; de Braud F; Procopio G
    Drug Des Devel Ther; 2016; 10():2167-72. PubMed ID: 27462141
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Recommendations on managing lenvatinib and everolimus in patients with advanced or metastatic renal cell carcinoma.
    Grande E; Glen H; Aller J; Argenziano G; Lamas MJ; Ruszniewski P; Zamorano JL; Edmonds K; Sarker S; Staehler M; Larkin J
    Expert Opin Drug Saf; 2017 Dec; 16(12):1413-1426. PubMed ID: 28920492
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 19.